Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Sponsor: The Aurum Institute NPC
Summary
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.
Official title: A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial
Key Details
Gender
All
Age Range
13 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2023-07-19
Completion Date
2025-12-31
Last Updated
2025-12-12
Healthy Volunteers
No
Interventions
Daily rifapentine and isoniazid for 4 weeks
Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
Weekly rifapentine and isoniazid for 12 weeks
Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
Locations (4)
The Byramjee Jeejeebhoy Medical Centre (BJGMC-JHU) CRS
Pune, Maharashtra, India
Yayasan KNCV - The Persahabatan Hospital, Jakarta
Jakarta, Jaya, Indonesia
Fundação Aurum (The Aurum Institute Mozambique)
Chokwé, Gaza Province, Mozambique
The Aurum Institute: Gavin J Churchyard Legacy Centre
Klerksdorp, North West, South Africa